Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of Etranacogene Dezaparvovec (Hemgenix) in Adult Males With Hemophilia B
2023-503765-37-00Phase 3Authorised
- Sponsor
- CSL Behring
- Start
- Mar 2024
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of etranacogene dezaparvovec in hemophilia B (HB), sponsored by CSL Behring. Primary endpoints: Number of Participants With Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs), Percentage of Participants with SAEs and AESIs and 1 more. Planned start Mar 2024; status: authorised.
02
Drugs
etranacogene dezaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2023-503765-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503765-37-00.